Alpha Cognition (Alpha Cognition) Debt-to-Revenue : N/A (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Alpha Cognition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.22 Mil. Alpha Cognition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Alpha Cognition's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

Alpha Cognition Debt-to-Revenue Historical Data

The historical data trend for Alpha Cognition's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Debt-to-Revenue Chart

Alpha Cognition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

Alpha Cognition Quarterly Data
	Jan20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial										N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Alpha Cognition's Debt-to-Revenue

For the Biotechnology subindustry, Alpha Cognition's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpha Cognition's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Cognition's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Alpha Cognition's Debt-to-Revenue falls into.

Alpha Cognition Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Alpha Cognition's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.22	+	0)	/	N/A
	=	N/A

Alpha Cognition's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.216	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Alpha Cognition Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpha Cognition (Alpha Cognition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (OTCPK:ACOGF) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

ACOG:Canada

Address

301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2

Website

https://www.alphacognition.com

Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.